The Agili-C implant supposts bone remodeling and cartilage regeneration, and it recieved FDA breakthrough designation in 2020, according to a news release. It is designed for International Cartilage Repair Society grade III or above knee-joint surface lesions.
“Agili-C is a technology I and others in the surgical community have been watching and waiting on for over 10 years,” Dr. Zaslav said in the release. “It is a novel implant supported by 4-years of data and counting from the multinational, randomized and controlled IDE clinical trial. Agili-C offers a cost efficient, off-the-shelf implant to fill an unmet need in my clinical practice.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
